Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SAB Biotherapeutics ( (SABS) ) just unveiled an update.
On July 21, 2025, SAB Biotherapeutics announced an oversubscribed $175 million private placement with participation from strategic investor Sanofi and other institutional investors. The proceeds are intended to fully fund the Phase 2b SAFEGUARD study of SAB-142 in Stage 3 autoimmune T1D and extend the company’s cash runway into mid-2028. The private placement includes the issuance of Series B nonvoting convertible preferred stock and warrants, potentially raising an additional $284 million if exercised in full. This financing is expected to bolster SAB’s position in the biopharmaceutical industry by supporting the development of its novel immunotherapy platform.
The most recent analyst rating on (SABS) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on SAB Biotherapeutics stock, see the SABS Stock Forecast page.
Spark’s Take on SABS Stock
According to Spark, TipRanks’ AI Analyst, SABS is a Neutral.
The overall stock score is primarily influenced by the company’s poor financial performance, as indicated by declining revenues and negative cash flows. While technical analysis shows bullish momentum, overbought conditions present a risk. Valuation concerns due to lack of profitability further weigh on the score. Corporate events positively impact governance but do not heavily influence the overall score.
To see Spark’s full report on SABS stock, click here.
More about SAB Biotherapeutics
SAB BIO is a clinical-stage biopharmaceutical company focused on developing human, multi-specific, high-potency immunoglobulins (IgGs) to treat and prevent immune and autoimmune disorders. Their lead asset, SAB-142, targets autoimmune type 1 diabetes (T1D) with a therapeutic approach aimed at delaying onset and potentially preventing disease progression. The company utilizes advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine, a transgenic animal with a human artificial chromosome, to produce targeted human IgGs without the need for human donors or convalescent plasma.
Average Trading Volume: 47,891
Technical Sentiment Signal: Hold
Current Market Cap: $23.88M
For a thorough assessment of SABS stock, go to TipRanks’ Stock Analysis page.